The FDA approved Cytokinetics’ aficamten (Myqorzo) tablets for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Myqorzo, an allosteric reversible myosin inhibitor, will compete directly with Bristol Myers Squibb’s camzyos despite differences in monitoring and safety restrictions; analysts expect the profile to affect market positioning. The approval includes a boxed warning for risk of heart failure due to reduced ejection fraction, and prescribing will require careful cardiac monitoring. Cytokinetics reported the clearance and cited the potential to address an unmet need in oHCM management. Investors responded favorably to the clearance, reflecting the commercial stakes for first‑in‑class and next‑generation myosin modulators in cardiology.